Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines

Background There is an ongoing debate about expanding the resection criteria for hepatocellular carcinoma (HCC) beyond the Barcelona Clinic Liver Cancer (BCLC) guidelines. We sought to determine the factors that held the most prognostic weight in the pre- and postoperative setting for each BCLC stage by applying a machine learning method. Methods Patients who underwent resection for BCLC-0, A and B HCC between 2000 and 2017 were identified from an international multi-institutional database. A Classification and Regression Tree (CART) model was used to generate homogeneous groups of patients relative to overall survival (OS) based on pre- and postoperative factors. Results Among 976 patients, 63 (6.5%) had BCLC-0, 745 (76.3%) had BCLC-A, and 168 (17.2%) had BCLC-B HCC. Five-year OS among BCLC-0/A and BCLC-B patients was 64.2% versus 50.2%, respectively ( p  = 0.011). The preoperative CART model selected α-fetoprotein (AFP) and Charlson comorbidity score (CCS) as the first and second most important preoperative factors of OS among BCLC-0/A patients, whereas radiologic tumor burden score (TBS) was the best predictor of OS among BCLC-B patients. The postoperative CART model revealed lymphovascular invasion as the best postoperative predictor of OS among BCLC-0/A patients, whereas TBS remained the best predictor of long-term outcomes among BCLC-B patients in the postoperative setting. On multivariable analysis, pathologic TBS independently predicted worse OS among BCLC-0/A (hazard ratio [HR] 1.04, 95% confidence interval [CI] 1.02–1.07) and BCLC-B patients (HR 1.13, 95% CI 1.06–1.19) undergoing resection. Conclusion Prognostic stratification of patients undergoing resection for HCC within and beyond the BCLC resection criteria should include assessment of AFP and comorbidities for BCLC-0/A patients, as well as tumor burden for BCLC-B patients.

[1]  T. Pawlik,et al.  Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group , 2018, Journal of Gastrointestinal Surgery.

[2]  K. Nan,et al.  Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages , 2017, Cancer management and research.

[3]  A. Venook,et al.  Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. , 2007, The oncologist.

[4]  K. Suh,et al.  Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma , 2017, The British journal of surgery.

[5]  Alessandro Vitale,et al.  Prospective validation of the Barcelona Clinic Liver Cancer staging system. , 2006, Journal of hepatology.

[6]  Shasha He,et al.  Effect of prophylactic TACE on 5-year survival of patients with hepatocellular carcinoma after hepatectomy , 2019, Oncology letters.

[7]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[8]  S. Strasberg,et al.  Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. , 2005, Journal of hepato-biliary-pancreatic surgery.

[9]  Chengwu Tang,et al.  Prophylactic hepatic artery infusion chemotherapy improved survival after curative resection in patients with hepatocellular carcinoma. , 2015, Hepato-gastroenterology.

[10]  I. Endo,et al.  Hepatocellular carcinoma tumour burden score to stratify prognosis after resection , 2020, The British journal of surgery.

[11]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[12]  S. Friedman,et al.  Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. , 2017, Journal of hepatology.

[13]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[14]  J. H. Kim,et al.  Hepatic resection compared to chemoembolization in intermediate‐ to advanced‐stage hepatocellular carcinoma: A meta‐analysis of high‐quality studies , 2018, Hepatology.

[15]  W. Lau,et al.  Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[16]  P. Rosenberg,et al.  Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Choti,et al.  A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group , 2013, Annals of surgery.

[18]  Leo Breiman,et al.  Classification and Regression Trees , 1984 .

[19]  Chia-Yang Hsu,et al.  A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. , 2010, Journal of hepatology.

[20]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2019, Clinical Liver Disease.

[21]  H. Eguchi,et al.  Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma. , 2016, Surgery.

[22]  I. Endo,et al.  The Tumor Burden Score: A New “Metro-ticket” Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors , 2018, Annals of surgery.

[23]  T. Pawlik,et al.  Trends in the Mortality of Hepatocellular Carcinoma in the United States , 2017, Journal of Gastrointestinal Surgery.

[24]  J. H. Kim,et al.  Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B , 2016, PloS one.

[25]  Dong-hao Wu,et al.  Nomogram for preoperative estimation of long-term survival of patients who underwent curative resection with hepatocellular carcinoma beyond Barcelona clinic liver cancer stage A1 , 2016, Oncotarget.

[26]  H. Petrowsky,et al.  Surgical therapy of hepatocellular carcinoma , 2005, European journal of gastroenterology & hepatology.

[27]  I. Endo,et al.  Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification , 2019, Annals of Surgical Oncology.

[28]  I. Endo,et al.  Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria. , 2020, Annals of surgery.

[29]  J. Marrero,et al.  Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort , 2005, Hepatology.